ANTGX
Price
$11.10
Change
-$0.00 (-0.00%)
Updated
Jun 2 closing price
Net Assets
551.01M
TROZX
Price
$26.46
Change
+$0.16 (+0.61%)
Updated
Jun 2 closing price
Net Assets
17.12B
Interact to see
Advertisement

ANTGX vs TROZX

Header iconANTGX vs TROZX Comparison
Open Charts ANTGX vs TROZXBanner chart's image
ANTGX vs TROZX Comparison Chart in %
View a ticker or compare two or three
VS
ANTGX vs. TROZX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANTGX is a Hold and TROZX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
TROZX has more cash in the bank: 17.1B vs. ANTGX (551M). ANTGX pays higher dividends than TROZX: ANTGX (4.60) vs TROZX (2.95). ANTGX was incepted earlier than TROZX: ANTGX (7 years) vs TROZX (6 years). ANTGX (0.83) is less costly to investors than TROZX (0.65). ANTGX is a more actively managed with annual turnover of: 71.00 vs. TROZX (15.00). ANTGX (0) and TROZX (0) have matching initial minimum investment requirements. TROZX annual gain was more profitable for investors over the last year : 30.42 vs. ANTGX (18.40). TROZX return over 5 years is better than : 91.32 vs. ANTGX (25.04).
ANTGXTROZXANTGX / TROZX
Total Expense Ratio0.030.00-
Annual Report Gross Expense Ratio0.830.65128%
Fund Existence7 years6 years-
Gain YTD7.87211.34669%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets551M17.1B3%
Annual Yield % from dividends4.602.95156%
Returns for 1 year18.4030.4260%
Returns for 3 years28.4992.9331%
Returns for 5 years25.0491.3227%
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATEX66.961.60
+2.45%
Anterix
FRAF56.63-0.39
-0.68%
Franklin Financial Services Corp
MNST88.24-0.86
-0.97%
Monster Beverage Corp
TFX125.24-2.33
-1.83%
Teleflex
VTGN0.58-0.07
-10.42%
VistaGen Therapeutics